Vyera Pharmaceuticals’ Commercialization Agreement with CytoDyn

Morgan Lewis represented Vyera Pharmaceuticals LLC in a commercialization and license agreement and a related supply agreement with CytoDyn Inc.

The agreement with CytoDyn Inc. grants an exclusive license to Vyera to market and distribute leronlimab in the United States for the treatment of HIV.

Vyera will pay upfront, regulatory and sales-based milestone payments totaling up to $87.5 million, as well as a royalty on net sales of 50%. Additionally, Vyera will purchase $4 million of CytoDyn common stock.

Vyera is a US-based biopharmaceutical company committed to developing and commercializing treatments that address serious and rare diseases with high unmet medical needs.

CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab. Leronlimab (PRO 140) is a viral-entry inhibitor for the treatment of deadly diseases such as HIV and cancer.

Morgan Lewis team advising Vyera was led by Partners Jay Carrigan (Picture) and Steve Navarro, along with partner Chris Halliday, associate Natalie Nicelli, and of counsel Al Bristow.

Involved fees earner: Albert Bristow – Morgan Lewis; James Carrigan – Morgan Lewis; Christopher Halliday – Morgan Lewis; Steven Navarro – Morgan Lewis; Natalie Nicelli – Morgan Lewis;

Law Firms: Morgan Lewis;

Clients: Vyera Pharmaceuticals;

Print Friendly, PDF & Email

Author: Ambrogio Visconti